MHC Class I On Target Cells Regulates CD4+ T-Cell Immunity

A fundamental shift in our understanding of the Major Histocompatibility Complex (MHC) Class I function on target cells has recently emerged from studies indicating that in addition to presenting peptides to CD8+ killer T cells, MHC Class I on target cells can regulate CD4+ T-cell-mediated death through the induction of ferroptosis. CD4+ T cells, often referred to as helper T cells, are known to coordinate several arms of the immune response. Thus, a role for MHC Class I on target cells in the regulation of CD4+ T-cell responses would have significant implications for our understanding of a variety of immune-related processes including infection control, cancer immunotherapy, organ transplantation, vaccine responses, and autoimmune disease.

Recent Research

The study identified a fundamental change in our current understanding of the function of MHC Class I on the surface of target cells. While it is well established that MHC I on the surface of a cell serves as a signal for destruction of that cell by CD8+ T cells, MHC I on the surface of a target cell can also function as a critical regulator of death of that cell mediated by CD4+ T cells through the induction of ferroptosis.

Why It Matters

For decades, the long-held view of the two arms of the adaptive immune system has served as the fundamental paradigm for the design of a wide array of diagnostic and therapeutic tools. We have described a so-called “class-restricted” dichotomy between MHC Class I presenting antigens to CD8+ cytotoxic T cells and MHC Class II presenting to CD4+ helper T cells. Understanding that MHC Class I on target cells can regulate CD4+ T cell mediated immune responses to cells under attack by the immune system offers both new promise and new risk for the treatment of a wide variety of diseases including infection, cancer, autoimmune disease and organ transplantation.

Beyond Antigen Presentation

The hallmark of a sustained adaptive immune response is the presence of CD4+ T cells that can activate B cells to produce antibodies, form long-lived CD8+ T cell memory, and induce a variety of inflammatory responses in tissues. Thus, in addition to modulating CD8+ T cell-mediated cytotoxicity, the influence of MHC I on target cells to activate, differentiate, and persist of CD4+ T cells will have significant consequences for vaccine-induced immunity, for the efficacy of cancer immunotherapy, and for the treatment of chronic autoimmune and inflammatory diseases. Importantly, a treatment designed to boost anti-tumor immunity by modifying antigen presentation could have the converse effect and exacerbate autoimmunity or chronic inflammation by increasing the level of CD4+ help provided to effector T cells.

What the Research Says

Interestingly, lacking or down-regulating MHC I expression on target cells has a set of consequences that are often quite opposite to what one would expect based on the long-held notion of an MHC class I restricted immune dichotomy. Instead of being more easily killed by CD8+ T cells, for example, tumor cells and virus infected cells that lack or down-regulate MHC I on their surface are found to be more readily killed by these cells as well. Interestingly, this is a result of these cells undergoing ferroptosis, an iron-dependent form of cell death that is characterized by the accumulation of lipid peroxides in cells.

The induction of ferroptosis in MHC I-deficient cells is associated with increased susceptibility to death by IFN-gamma treated CD8+ T cells. Here, we have identified the IFN-gamma-induced IRF1-ACSL4 pathway that induces ferroptosis in target cells by promoting the accumulation of lipid peroxides.

System-Level Implications

This new function of MHC I on non-immune target cells will have huge impacts in terms of new diagnostic tests, in terms of how new emerging therapies will be reimbursed by payers and in terms of new care pathways for patients with a range of diseases. In terms of tests, novel biomarkers will be required on non-immune target cells for the diagnosis of cancer as well as for a range of other diseases. In terms of tests and treatments for which there will be a need for reimbursement by payers and for new health care pathways, it will be necessary for the new tests and treatments to be deemed to be medically necessary and therefore to be cost effective. Workforce training will also be required to interpret data from antigen presentation profiles of presentation and to take action as a result of this data. Additional training will be required for a number of different individuals including for example additional training for pathologists and for laboratory scientists as well as for a number of different clinicians.

Who It Affects

Patients

Cancer patients, patients with infectious diseases and transplant patients all can be affected by this new aspect of immunology.

Patients Treated for Cancer

Cancer Patients: The understanding of MHC Class I expression on tumor cells and of surrounding tissues will help in the treatment of cancer patients. Therapies that promote antitumor CD4+ T cell help, such as vaccines, checkpoint inhibitors and adoptive cell transfer can be helped or hindered by high MHC Class I expression on tumor cells. In some cases high MHC Class I expression on tumor cells can even support a cytotoxic function of CD4+ T cells. In other cases a shift in the immune environment of a tumor to an exhausted or even regulatory phenotype could be promoted. High numbers of CD4+ effector T cells have been found in several types of cancer including melanoma and mismatch-repair-deficient (MMRd) colon cancers that have low MHC I expression on their tumor cells. This supports a tumor suppressive, ‘back-up’ function of CD4+ effector T cells that can control even CD8+ T cell non-eliminvasive tumors.

Transplant Recipients

The same changes in expression of surface antigens could influence the fate of organ transplants. As for cancer, the immune-tolerance that is required for graft acceptance can be modulated by MHC I on the surface of donor cells, whether these cells induce rejection by CD8+ cells or are destroyed by CD4+ cells and thus cause chronic rejection. Moreover, these cells can also be targeted by CD4+ cells to induce tolerance. Studies of Graft-Versus-Host Disease (GVHD) have shown that intestinal epithelial cells (IECs) of the recipient are sensitive to attack by CD4+ T cells even when their activation is low. The absence of MHC I on the surface of these cells could therefore play a role in GVHD. Conversely, the presence of MHC I on the surface of some IECs can protect them from such an attack. Importantly, our work has also shown that cells lacking MHC I are specifically destroyed by cytotoxic CD8+ T cells, in contrast to what is expected.

Patients with Infectious Diseases

Individuals suffering from chronic diseases which are caused by infections could also potentially benefit from an increased MHC I display on their target cells. Chronic diseases which are caused by infections lead to a strong CD4+ immune response. The extent to which a pathogen or the cells that the pathogen has infected can change the MHC I display on these cells could explain why a patient is not able to clear the infection. Furthermore, these changes in the MHC I display on the surface of the target cells of an infection could also be the reason why a vaccine against this infection is not effective in a particular patient.

Payers, Policymakers, and Clinical Leaders

Payers, Policymakers, and Clinical Leaders: Payers, such as Medicare and private health insurance companies, as well as health care policy makers and clinical leaders will be affected by the measurement of MHC Class I on the surface of tumors and the subsequent manipulation of this antigen presentation pathway to enhance the effects of current therapies as well as combination immunotherapies. Advanced diagnostics to measure MHC Class I will need to be shown to have clinical utility in order to be considered for coverage by payers. Clinical leaders and the regulatory bodies (e.g. FDA) as well as professional societies will need to establish updated clinical practice guidelines that translate current knowledge of the mechanisms of action of current and experimental therapies to optimize their use in the clinical setting.

What Changes

• Diagnostic practice may broaden to include assessments of MHC Class I expression on target tissues, not just on professional antigen‑presenting cells, to better predict therapy response and immune risk.
• Treatment selection could shift: clinicians may consider how therapies that alter antigen presentation, such as epigenetic drugs, oncolytic viruses, or cytokines, affect both CD8+ and CD4+ arms, and tailor combinations accordingly.
• Clinical monitoring standards may evolve to track CD4+ function and phenotype after interventions that change MHC Class I, to detect early signs of unwanted inflammation, loss of efficacy, or evolving autoimmunity.
• Research and policy priorities may move toward developing safe ways to modulate antigen presentation in tissues, along with frameworks to evaluate cost, equity, and long‑term safety before wide adoption.

Clinical and Care Considerations

Clinical Translational

These treatments can have positive effects on a number of different arms of the immune response but there will also be potential adverse effects on these different arms of the immune response and therefore interventions that change MHC Class I display on the surface of cells that present antigens to the immune system must be used with great caution and their effects on all of the different arms of the immune response need to be studied in great detail by treating clinicians.

Patient Selection

This same view will also be very important when considering which patients will most likely benefit from treatments that affect MHC Class I display on the surface of tissues. For the majority of situations, manipulation of MHC Class I on the surface of tissues of most patients is not likely to induce beneficial CD4+ responses, whereas in other cases, such manipulation could result in beneficial effects on antibody production and immune regulation. For these latter situations, reliable biomarkers (i.e. tests) will be needed to first establish whether, in individual cases, such treatments will have beneficial effects on CD4+ responses.

Safety Monitoring

Monitoring the effects on safety of changing antigen presentation and its consequences for CD4+ help, for antibody production and for the overall immune regulation would be very important. Some of the effects might only become apparent weeks or even months after an intervention has been given and could be very serious for the patient. The clinician would need to explain the theoretical risks and consequences to the patient and make a shared decision whether to intervene or not, and if so which intervention and on what terms.

Ferroptosis

CD4+ T cells undergo ferroptosis, or lipid peroxidation-mediated cell death, and it has recently been found that driving such ferroptosis can actually drive immune responses. In models of MHC I-deficient mice, treatment with the iron chelator deferasirox (DFX) or with ferroptosis inhibitors such as ferrostatin led to reduced CD4+ T cell lipid peroxidation and improved survival, in part through reduction of MHC I-independent presentation of antigens to CD8+ T cells and in part through a direct effect on CD4+ T cells, which can present antigens to

Clinicians may eventually utilize:

• Iron Homeostasis Markers: Monitoring intestinal iron levels could serve as a biomarker for GVHD severity.
• Combination Therapies: Enhancing CD4+ T-cell activity alongside ferroptosis-inducing agents could proactively treat immune-cold tumors that have lost MHC I expression.

System and Policy Implications

Payers and regulators will need to determine the level of evidence that would support the use of new antigen presentation tests and treatment as well as coverage and reimbursement for their use. Real world evidence studies and registries can be useful for capturing data on long-term outcomes as well as rare adverse effects.

Workforce: The health system needs to have the lab capacity and training for the pathologists and the clinicians to be able to accurately interpret the results of these more nuanced antigen presentation tests and to incorporate this information into the patient’s care plan.

Looking Ahead

This way, translation of current knowledge into patient centered studies (disease control, remission, graft survival, reduced autoimmunity) is most productive. However, also issues of safety and of ethics of interventions of tissue antigen presentation for adaptive immune responses have to be developed.

Future Innovation

Future innovation in cancer treatment and in the management of a variety of chronic autoimmune diseases will be based upon new diagnostic tools and upon targeted therapeutics that, for example, up- or down-regulate the amount of MHC I presented on the surface of various types of target cells in the body. This will, in turn lead to the implementation of new combination therapies that, for example, allow for the alignment of CD4+ help with a variety of desired effector functions. The use of these diagnostic tools will allow for a better selection of patients for a variety of forms of immune modulation.

Health Equity & Access

For those emerging treatments for modulating tissue antigen presentation that show promise, there are also many promising diagnostics for helping to determine the optimal immunomodulatory strategy for a given patient. However, the majority of these treatments are expensive, and most are administered in specialized centers within university medical centers. Thus, there are significant health equity and access concerns that must be addressed by the leaders of health care systems and by the payers as promising new diagnostics and treatments for the mechanics of antigen presentation are translated into clinical use.

Bottom Line

MHC Class I on target cells can be used to regulate CD4+ T cells. This new understanding of a familiar immune mechanism can lead to practice in many medical areas. The practical translation of this new understanding into safe, effective health care for many patients will require investment in new tests and monitoring of patients on treatment as well as a variety of approaches to tailor the use of current and future therapies to the individual patient’s immune profile. Additional efforts will be required to provide evidence for new uses of current and future therapies as well as the necessary health care systems infrastructure to translate new understanding of antigen presentation into safe, effective health care of individual patients.

Reference

1. Lauder E, Gondal M, Wu MC, et al. MHC class I on target cells regulates CD4+ T cell-mediated immunity. Nat Immunol. Published online March 24, 2026. doi:10.1038/s41590-026-02480-z